Faeth Therapeutics, Inc. (FTH) stock
FTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.65−2.70 (-20.22%)
Close on Nov 12, 2026Market cap $275.20MP/E –Yield –
Faeth Therapeutics cash
Cash and short-term investments held at the end of each period.
Faeth Therapeutics's cash was $186.44M at Jun 30, 2026. For fiscal 2025 it was $21.18M, down 48.8% from the year before. The highest annual figure on record is $147.60M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.18M | -48.8% |
| FY2024 | Dec 31, 2024 | $41.34M | -37.1% |
| FY2023 | Dec 31, 2023 | $65.76M | -38.6% |
| FY2022 | Dec 31, 2022 | $107.12M | -27.4% |
| FY2021 | Dec 31, 2021 | $147.60M | +789.4% |
| FY2020 | Dec 31, 2020 | $16.60M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $186.44M | +551.3% |
| Q1 FY2026 | Mar 31, 2026 | $202.79M | +490.7% |
| Q4 FY2025 | Dec 31, 2025 | $21.18M | -48.8% |
| Q3 FY2025 | Sep 30, 2025 | $25.04M | -46.7% |
| Q2 FY2025 | Jun 30, 2025 | $28.63M | -45.3% |
| Q1 FY2025 | Mar 31, 2025 | $34.33M | -40.9% |
| Q4 FY2024 | Dec 31, 2024 | $41.34M | -37.1% |
| Q3 FY2024 | Sep 30, 2024 | $47.00M | -34.7% |
| Q2 FY2024 | Jun 30, 2024 | $52.29M | -33.7% |
| Q1 FY2024 | Mar 31, 2024 | $58.08M | -39.2% |
| Q4 FY2023 | Dec 31, 2023 | $65.76M | -38.6% |
| Q3 FY2023 | Sep 30, 2023 | $72.01M | -38.2% |
| Q2 FY2023 | Jun 30, 2023 | $78.84M | -36.3% |
| Q1 FY2023 | Mar 31, 2023 | $95.51M | -29.9% |
| Q4 FY2022 | Dec 31, 2022 | $107.12M | -27.4% |
| Q3 FY2022 | Sep 30, 2022 | $116.56M | -25.6% |
| Q2 FY2022 | Jun 30, 2022 | $123.71M | -23.9% |
| Q1 FY2022 | Mar 31, 2022 | $136.22M | -19.6% |
| Q4 FY2021 | Dec 31, 2021 | $147.60M | +789.4% |
| Q3 FY2021 | Sep 30, 2021 | $156.66M | – |
| Q2 FY2021 | Jun 30, 2021 | $162.50M | – |
| Q1 FY2021 | Mar 31, 2021 | $169.42M | – |
| Q4 FY2020 | Dec 31, 2020 | $16.60M | – |
See a number that looks wrong?